Proteomics prognostications:
>>The Demand for Drug Discovery Is Pushing Proteomics Technology Vendors To Develop Innovative Platforms
SAN MATEO, Calif., Feb. 25 /PRNewswire/ -- Front Line Strategic Consulting, Inc., a leader in strategic consulting and market analysis for the Life Sciences industries, today announced the completion of its new Strategic Market Report(TM) series, Proteomics: A Strategic Technology and Market Assessment. Front Line's report includes an in-depth analysis of the market drivers, key companies and market shares, and strategic analysis of the proteomics market. The worldwide proteomics market is projected to experience a 12% overall compound annual growth rate (CAGR) for the next five years. Protein separation is the largest market segment with an estimated 51% market share in 2003. The U.S. market share is at 45%, with Europe at 40% and Japan at 10%.
"To fully understand disease models and discover novel therapeutics, it is imperative that all the proteins involved in pathways are identified and thoroughly characterized since they are the ultimate disease effectors. Consequently proteomics plays an important role in the drug discovery process. Pharmaceutical and biotechnology companies will utilize proteomic technologies to gain further insight into disease mechanisms to develop novel drugs," said Charles Chang, analyst, strategic market reports for Front Line Strategic Consulting, Inc.
Proteomics is the identification, quantification, and characterization of all the proteins in a particular cell, organ, or organism. The proteomics market can be divided into four segments: protein separation, protein characterization, content and informatics, and services. The factors driving the development include the broad utility of the technology, easier target identification, and shifting FDA requirements. The U.S. comprises a major portion of the development and sales of proteomics products driven by the launch of innovative new products and improved technologies. The emergence of protein microarrays is an example of a technological advancement that will likely become an important tool for proteomic studies. In addition, the increasing amount of proteomic data generated after the completion of the Human Genome Project has increased demand for data management software, a segment that will likely experience 15% compound annual growth over the next few years. While Front Line expects the category to continue to expand, limiting factors to proteomics are the presence of difficult to isolate proteins, limited demonstrated financial value of the technologies, and high initial investment requirements.
About Front Line
Headquartered in San Mateo, Calif., Front Line is a leader in strategic consulting and market analysis for the Life Sciences industries, offering strategic business intelligence through exclusive consulting engagements and comprehensive strategic market reports of key therapeutic and technology areas. Front Line was founded in 1992 and specializes in combining diligent research methodology with intelligent strategic planning for their pharmaceutical and biotechnology customers. www.frontlinesmc.com
CONTACT: Stan Shelsta, stan@frontlinesmc.com, ext. 145, or Al Manzano, al@frontlinesmc.com, ext. 135, both of Front Line Strategic Consulting, Inc., +1-650-525-1500. <<
Cheers, Tuck |
